Altimmune, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Altimmune is a clinical-stage biopharmaceutical company developing peptide-based therapeutics, including pemvidutide, a GLP-1/glucagon dual receptor agonist being studied for obesity and metabolic liver disease (MASH).
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| WEAVER GREGORY LChief Financial Officer | Buy | $16K | 10,000at $1.62 | Nov 13, 2026 |
| Durso Jerome BenedictPresident and CEO | Buy | $50K | 30,700at $1.62 | Nov 13, 2026 |
| Pisano WayneDirector | Buy | $16K | 10,000at $1.64 | Nov 13, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ALT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.